Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

The former President of Pfizer Global Manufacturing gifted $50 million to his former school, Northfield Mount Hermon.

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Sales of PFE’s COVID Products Declining Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, are declining due to lower demand following the end of the pandemic. However, sales of both ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.6% during trading on Tuesday after Citigroup lowered their price target on the stock from $30.00 to $29.00. Citigroup currently has ...

Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.